Clinical Trials
26 trialsNCT07595874 2026-05-27
NEST3
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06567782 2026-05-22
AZUR-4
GlaxoSmithKline
Phase 2 Recruiting
NCT06890624 2026-05-22
OPTICAL-3
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06580574 2026-05-15
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Peking University
Phase 2 Recruiting
NCT07058012 2026-05-15
EMPIRE
NSABP Foundation Inc
Phase 2 Recruiting
NCT05513742 2026-05-06
COMPANION-003
Compass Therapeutics
Phase 2 Completed
NCT07224022 2026-05-06
NACho
Duke University
Phase 2 Not yet recruiting
NCT05961709 2026-05-04
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06778382 2026-04-28
Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07549906 2026-04-24
Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05308446 2026-04-21
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05197322 2026-04-17
NEOPRISM-CRC
University College, London
Phase 2 Recruiting
NCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT07515963 2026-04-07
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.
Zhongnan Hospital
Phase 2 Not yet recruiting
NCT07510932 2026-04-06
FIRST-K
Korea University Anam Hospital
Phase 2 Not yet recruiting
NCT04963283 2026-03-31
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT05806931 2026-03-18
SCOTI
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT07011576 2026-03-18
FRUITFUL
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT07432399 2026-03-06
PILDI
Institute of Oncology Ljubljana
Phase 2 Recruiting
NCT03026140 2026-03-05
NICHE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05672108 2026-03-05
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
Phase 2 Recruiting